TB-500
Peptide Science & Research
ESTABLISHED
STILL BEING STUDIED
NOT YET ESTABLISHED
What Is TB-500?
A Research Overview of TB-500 and Its Relationship to Thymosin Beta-4
TB-500 is a synthetic peptide corresponding to an acetylated short sequence derived from the actin-binding region of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide involved in cellular processes associated with movement, repair and tissue biology.
Research surrounding this biological pathway has generated scientific interest in cell migration, angiogenesis, extracellular-matrix remodeling and wound-repair mechanisms.
However, an important distinction runs throughout this page: much of the established literature concerns full-length thymosin beta-4 or its biological domains, rather than TB-500 itself.
Research status: Investigational / limited direct human evidence.
Important: TB-500 and thymosin beta-4 are related, but they are not the same molecule. Full-length thymosin beta-4 contains 43 amino acids, while TB-500 represents a much shorter sequence derived from its central region. Findings involving full-length Tβ4 therefore provide important biological context for studying TB-500, but they should not automatically be interpreted as evidence that TB-500 produces the same effects.
Why Are Researchers Interested?
TB-500 sits within a particularly interesting area of regenerative biology because its sequence originates from a functionally important region of thymosin beta-4. Research surrounding this pathway has explored:
What The Research Suggests
The Actin-Binding Region Is Biologically Interesting
One of the strongest mechanistic findings comes from research examining thymosin beta-4 and its active sequences.
Researchers reported that the short actin-binding motif associated with the central region of Tβ4 was important for angiogenic activity. Experimental assays found activity involving endothelial-cell migration and blood-vessel sprouting.
Why it matters: TB-500 is derived from this scientifically active region, providing a biological rationale for continued investigation.
Wound Repair Has Been Extensively Studied — Primarily With Tβ4
Thymosin beta-4 has produced notable findings in preclinical wound-repair research.
In a rat full-thickness wound model, researchers reported increased re-epithelialization, collagen deposition and angiogenesis following Tβ4 treatment.
Additional research has investigated Tβ4 in burn wounds and other tissue-repair models.
Important distinction: These studies examined thymosin beta-4 and should not be presented as direct clinical evidence for TB-500.
Matrix Remodeling May Be Part of the Biology
Experimental research found that thymosin beta-4 increased expression of several matrix metalloproteinases associated with wound remodeling.
Researchers also reported that the central actin-binding domain reproduced activity related to metalloproteinase induction, strengthening scientific interest in this particular region of the molecule.
Newer TB-500-Specific Research Adds an Interesting Twist
A 2024 study examined TB-500 itself, along with metabolites formed after the peptide was broken down.
Researchers found that the parent TB-500 did not demonstrate significant wound-healing activity in the particular fibroblast assay used, while one metabolite — Ac-LKKTE — did show significant activity.
The researchers proposed that some biological activity previously associated with TB-500 could potentially involve its metabolites rather than the intact parent peptide.
This creates an interesting emerging research question: Could some of TB-500's biological activity depend on what happens after the peptide is metabolized? That remains an area requiring further study.
Evidence At A Glance
Thymosin Beta-4 Biology
Tβ4 has an established experimental research history involving actin biology, cellular migration, angiogenesis and tissue repair.
The LKKTETQ Region
The central actin-binding sequence from which TB-500 is derived has demonstrated biological activity in experimental models.
TB-500 & Its Metabolites
Recent research is beginning to distinguish the activity of TB-500 itself from the activity of metabolites produced after administration.
Tβ4 ≠ TB-500
Evidence involving full-length thymosin beta-4 cannot automatically be attributed to TB-500.
Human Evidence
FDA reported in its 2026 review that it had not identified human studies in which TB-500 was administered to patients to treat a disease or condition.
Safety & Limitations
The greatest limitation in interpreting TB-500 research is the difference between TB-500-specific evidence and the substantially larger body of research involving full-length thymosin beta-4.
FDA's current evaluation states that it has not identified human exposure data for drug products containing the thymosin beta-4 fragment known as TB-500. FDA also notes unresolved concerns involving immunogenicity, aggregation, peptide-related impurities and the absence of sufficient toxicology information.
Therefore: Human safety has not been established. Clinical effectiveness has not been established. Optimal dosing has not been established. Long-term safety has not been established. Tβ4 findings should not automatically be extrapolated to TB-500.
Regulatory Status
TB-500 is not an FDA-approved drug.
FDA identifies the substance as: “Thymosin beta-4, fragment (LKKTETQ), also known as TB-500.” The agency states that compounded products containing this fragment may present immunogenicity concerns and that it lacks sufficient human exposure and safety information to determine whether administration could cause harm.
FDA's 2026 Review
In its 2026 evaluation of TB-500 for proposed use in wound healing, FDA reported that it did not identify clinical evidence involving administration of TB-500 to patients for treatment of a disease or condition.
FDA therefore concluded that evidence was insufficient to evaluate its effectiveness for wound healing.
Important Scientific Distinction
Full-length thymosin beta-4 has been studied much more extensively than TB-500.
This difference matters when evaluating claims. Research involving Tβ4 can help explain why scientists are interested in TB-500's sequence, but it does not establish TB-500 as having the same safety profile or therapeutic effects.
Regulatory Status — TB-500: Not FDA-approved. TB-500 is identified by FDA as the thymosin beta-4 fragment (LKKTETQ). FDA has not identified human exposure data for drug products containing this fragment and notes unresolved concerns involving immunogenicity, aggregation, peptide-related impurities and insufficient toxicology information. In its 2026 review, FDA did not identify clinical evidence involving administration of TB-500 to patients and concluded that evidence was insufficient to evaluate its effectiveness for wound healing.
TB-500 vs. Thymosin Beta-4
Related — But Not Interchangeable. TB-500 and thymosin beta-4 are related, but they are not the same molecule.
TB-500
Ac-LKKTETQ — A short synthetic peptide derived from the central actin-binding region associated with thymosin beta-4. Research emphasis: Metabolism • fragment biology • actin-related mechanisms • emerging wound-repair research.
Thymosin Beta-4
43-amino-acid naturally occurring peptide — A substantially larger molecule with multiple biologically active regions. Research emphasis: Cell migration • angiogenesis • wound repair • inflammation • tissue regeneration • actin regulation.
Why The Difference Matters: Research on thymosin beta-4 provides a valuable scientific foundation for understanding why the TB-500 sequence is of interest. However, because TB-500 represents only one region of the larger molecule, research findings from full-length Tβ4 should not automatically be treated as TB-500 findings. That distinction makes TB-500 an especially interesting subject for future direct research.
Research & Publications
The Actin Binding Site on Thymosin Beta-4 Promotes Angiogenesis
Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK — FASEB Journal, 2003
Investigated the actin-binding motif of Tβ4 and its role in endothelial migration, vessel sprouting and angiogenesis.
View on PubMedThymosin Beta-4 Accelerates Wound Healing
Malinda KM et al. — Journal of Investigative Dermatology, 1999
Animal research examining re-epithelialization, collagen deposition, angiogenesis and wound contraction following Tβ4 exposure.
View on PubMedBiological Activities of Thymosin Beta-4 Defined by Active Sites in Short Peptide Sequences
Morris DC et al. — FASEB Journal, 2010
Examined different biologically active regions of Tβ4 and identified the LKKTETQ-containing central region as relevant to angiogenesis, wound healing and cell migration.
View on PubMedThymosin Beta-4: Actin-Sequestering Protein Moonlights to Repair Injured Tissues
Goldstein AL, Hannappel E, Kleinman HK — Trends in Molecular Medicine, 2005
Review of Tβ4 biology and its potential roles in tissue repair and remodeling.
View on PubMedThymosin Beta-4 Promotes Matrix Metalloproteinase Expression During Wound Repair
Philp D et al. — Journal of Cellular Physiology, 2006
Investigated matrix metalloproteinase activity and the contribution of the central actin-binding domain during experimental wound repair.
View on PubMedSynthesis and Characterization of the N-Terminal Acetylated 17–23 Fragment of Thymosin Beta-4 Identified in TB-500
Esposito S et al. — Drug Testing and Analysis, 2012
Analytically identified TB-500 as the acetylated 17–23 fragment of human thymosin beta-4.
View on PubMedSimultaneous Quantification of TB-500 and Its Metabolites
Rahaman KA et al. — Journal of Chromatography B, 2024
Investigated TB-500 metabolism and wound-healing activity in vitro, raising the possibility that biological activity may differ between the parent compound and its metabolites.
View on PubMedTB-500: Research Is Still Developing.
TB-500 occupies an intriguing intersection between established thymosin beta-4 biology and much newer fragment-specific research.
The biological region from which TB-500 originates has a substantial research history involving cellular migration, angiogenesis and tissue-repair mechanisms. At the same time, direct evidence involving TB-500 itself remains much more limited.
Understanding that distinction provides a more accurate picture of the science — and highlights why direct research on TB-500, its metabolites and their biological activity remains important.
Educational information only — not medical advice.